Repligen Corporation (RGEN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Repligen Corporation stock (RGEN) is currently trading at $114.32. Repligen Corporation PE ratio is 135.23. Repligen Corporation PS ratio (Price-to-Sales) is 8.87. Analyst consensus price target for RGEN is $187.28. WallStSmart rates RGEN as Underperform.
- RGEN PE ratio analysis and historical PE chart
- RGEN PS ratio (Price-to-Sales) history and trend
- RGEN intrinsic value — DCF, Graham Number, EPV models
- RGEN stock price prediction 2025 2026 2027 2028 2029 2030
- RGEN fair value vs current price
- RGEN insider transactions and insider buying
- Is RGEN undervalued or overvalued?
- Repligen Corporation financial analysis — revenue, earnings, cash flow
- RGEN Piotroski F-Score and Altman Z-Score
- RGEN analyst price target and Smart Rating
Repligen Corporation
📊 No data available
Try selecting a different time range
RGEN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Repligen Corporation (RGEN)
RGEN trades 246% above its Graham fair value of $40.25, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Repligen Corporation (RGEN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in eps growth, institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Repligen Corporation (RGEN) Key Strengths (3)
Earnings per share surging 160.00% year-over-year
112.78% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Repligen Corporation (RGEN) Areas to Watch (7)
Very low returns on shareholder equity
Very expensive relative to growth, significant premium
Very thin margins with limited operational efficiency
Very expensive at 8.9x annual revenue
Premium pricing at 3.0x book value
Thin profit margins with limited profitability
Solid revenue growth at 18.10% per year
Supporting Valuation Data
Repligen Corporation (RGEN) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Market Cap. Growth metrics are encouraging with EPS Growth at 160.00%.
The Bear Case
The primary concerns are Return on Equity, PEG Ratio, Operating Margin. Some valuation metrics including PEG Ratio (8.23), Price/Sales (8.87), Price/Book (3.04) suggest expensive pricing. Growth concerns include Revenue Growth at 18.10%, which may limit upside. Profitability pressure is visible in Return on Equity at 2.40%, Operating Margin at 8.26%, Profit Margin at 6.62%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 2.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 18.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and PEG Ratio are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RGEN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RGEN's Price-to-Sales ratio of 8.87x trades 36% below its historical average of 13.79x (24th percentile). The current valuation is 76% below its historical high of 37.33x set in Jun 2015, and 88600% above its historical low of 0.01x in Jan 2012.
Compare RGEN with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Repligen Corporation (RGEN) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Repligen Corporation is a strong growth company balancing expansion with improving profitability. Revenue reached 738M with 18% growth year-over-year. Profit margins are thin at 6.6%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 240.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 17M in free cash flow and 26M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Repligen Corporation push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 135.2x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Repligen Corporation.
Bottom Line
Repligen Corporation offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Repligen Corporation(RGEN)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.